Vis børsmeldingen
Administration (FDA) has approved Fast Track Designation for bemcentinib for the
treatment of elderly patients with acute myeloid leukaemia (AML) whose disease
has relapsed. There are currently no marketed drugs specifically approved for
all relapsed AML patients, representing a significant unmet medical need.
BerGenBio has ongoing phase 2 trials in this indication and plans to seek
regulatory advice from the FDA and European Medicines Agency (EMA) to determine
the optimal regulatory path for bemcentinib in relapsed AML.
Fast Track is a process designed to facilitate the development and expedite the
review of drugs to treat serious conditions and fill an unmet medical need. The
purpose is to get important new drugs to the patient earlier. Fast Track
addresses a broad range of serious conditions. Filling an unmet medical need is
defined as providing a therapy where none exists or providing a therapy which
may be potentially better than available therapy. A drug that receives Fast
Track designation is eligible for the following:
· More frequent meetings with FDA to discuss the drug’s development plan and
ensure collection of appropriate data needed to support drug approval
· More frequent communication from FDA about such things as the design of the
proposed clinical trials and use of biomarkers
· Eligibility for Accelerated Approval and Priority Review, if relevant
criteria are met
· Rolling Review, which means that a drug company can submit completed
sections of its Biologic License Application (BLA) or New Drug Application (NDA)
for review by FDA, rather than waiting until every section of the NDA is
completed before the entire application can be reviewed. BLA or NDA review
usually does not begin until the drug company has submitted the entire
application to the FDA
Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are
thrilled that bemcentinib has been granted Fast Track Designation. Not only does
this make us eligible for accelerated approval and priority review, but it
serves as an important validation of bemcentinib in this significant unmet
medical need we are trying to address. Currently, bemcentinib is in expanded
Phase II trials in the U.S. and Europe for the treatment of AML and the Company
has recently announced positive interim top line data.”
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL inhibitors, therefore, have potential high
value at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.
About bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, as monotherapy and in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy). Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.
About AML
Acute myeloid leukemia (AML) is the most common type of aggressive leukemia in
adults, which has the lowest survival rate for all types of leukemia. In 2018,
it is estimated there will be nearly 20,000 new cases of AML diagnosed in the
United States. Many AML patients older than age 60 are unable to tolerate
intensive induction chemotherapy treatment.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer and
leukaemia. A first-in-class functional blocking AXL antibody (BGB149) and an AXL
-ADC (ADCT-601) are undergoing phase I clinical testing. In parallel, BerGenBio
is developing a companion diagnostic test to identify those patient populations
most likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Carina Jurs, Consilium Strategic
Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Kilde
Da var jeg med inn i den da 
